No detectable increase in pregnancy risks after GLP-1 exposure around conception, largest review to date finds
Medical Xpress reports on a systematic review and meta-analysis in Med, led by City St George's, University of London, pooling 10 observational studies covering 2,118,215 pregnancies, 8,325 exposed to GLP-1 receptor agonists around conception. It found no clearly detectable increase in miscarriage, stillbirth, congenital anomalies or other adverse outcomes. Authors stress this does not establish pregnancy safety and say current guidance to stop before planned pregnancy stands.
Why it matters: Relevant to women of reproductive age using GLP-1 weight-loss or diabetes medicines, and to clinicians who prescribe them or counsel patients about pregnancy.
A summary of another publisher's reporting, written with AI and checked automatically against the story. The reporting belongs to medicalxpress.com. October 5, 2026.